| INTRODUCTION
One of the key events in the progression of cancer metastasis is the migration of circulating tumor cells through vascular endothelium. [1] [2] [3] [4] Tumors induce abnormal endothelial permeability by various mechanisms in order to promote this process of cancer cell invasion and recently inhibition of tumor-induced vascular permeability has been shown to attenuate metastasis in vivo.
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Several clinical studies have suggested that low molecular weight heparin (LMWH) may confer a survival benefit in sub-groups of patients with cancer. [10] [11] [12] [13] [14] This benefit appears to be restricted to patients with early-stage disease, suggesting that it may be mediated through suppression of metastasis. LMWH influences cell signalling pathways implicated in tumor dissemination in vitro and has been
shown to attenuate abnormal vascular permeability in experimental models of sepsis and acute lung injury.
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The risk of bleeding associated with LMWH precludes its use in cancer in settings other than the treatment or prevention of thrombosis. 23 Consequently, LMWH could only be utilized for prevention of metastasis if the associated bleeding risk can be addressed.
In the present study, we aimed to characterize the effects of LMWH in enhancing the barrier function of vascular endothelium and to explore the molecular mechanism underlying this phenomenon. We also aimed to investigate the relative anticoagulant and cytoprotective properties of a fraction of LMWH tinzaparin composed primarily of short heparin polysaccharide chains. In addition,
we explored the potential additive or synergistic effects on barrier function which are observed when sub-anticoagulant concentrations of LMWH are combined with a statin (a lipid-lowering agent which has also been shown to stabilize endothelial barrier function in vitro).
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| MATERIALS AND METHODS
| Materials
EA.hy926 (a PAR-1 expressing human umbilical vein endothelial cell line) was a kind gift from Dr. C. Edgell (University of North Carolina,
Chapel Hill, North Carolina, USA). DU145, a metastatic prostate carcinoma cell line was from ATCC (Manassas, VA, USA). Polyethylene
terephthalate (PET) membrane trans-well inserts (Millicell Hanging
Cell Culture Inserts; 6-well plate, 3.0 μm pore size, 4.5 cm 
| Endothelial barrier permeability assay
An in vitro assay of endothelial barrier function was established as previously described. 26, 27 Briefly, EA.hy926 human endothelial cells were seeded on PET membrane trans-well inserts (3.0 μm pore size) and cultured in DMEM supplemented with 10% FBS. At 72 hours, the confluent EA.hy926 monolayers were washed in phosphate buffered saline (PBS), and re-incubated in serum-free DMEM. An Evans Blue (0.67 mg/mL)-conjugated bovine serum albumin (BSA, 4%) solution was added to the inner chamber of each trans-well and aliquots of cell culture media from the outer chamber of the trans-well plate were then sampled at 2-minute intervals. The permeability of the endothelial cell layers was determined through the spectrophotometric measurement of the increase in absorbance in the sampled media as a result of flux of the albumin solution through the endothelial cell layer over time.
| Tumor cell trans-endothelial migration assay
Endothelial monolayers were grown on PET trans-well membrane inserts (8 μm pore size) as outlined above. At 72 hours, the inserts were washed in sterile PBS and returned to wells containing FBSsupplemented DMEM. A calcein blue AM-labelled DU145 prostate carcinoma cell suspension was incubated with the endothelial
Essentials
• Inhibition of tumor cell trans-endothelial migration inhibits metastasis formation.
• Low molecular weight heparin (LMWH)-mediated endothelial barrier protection was investigated.
• LMWH enhanced endothelial barrier activity and attenuated tumor cell transmigration.
• The cytoprotective activity of LMWH did not appear to be dependent on anticoagulant activity. monolayer and at 3 hours the extent of DU145 cell trans-endothelial migration was assessed by measuring the increase in fluorescence absorbance of the culture media in the outer chamber of the transwell as a consequence of migration of the DU145 cells through the endothelial monolayer. 
| Characterisation
| Cleavage of endothelial cell surface heparan sulphate proteoglycans (HSPG)
Monolayers of EA.hy926 endothelial cells grown on PET membrane trans-well inserts were incubated with heparinase III (1 U/mL) for 2 hours at 37°C. The cell culture supernatant was aspirated and the monolayers washed three times with PBS and re-incubated with fresh cell culture media. 
| Statistical analysis
All experiments were performed at least in duplicate with results expressed as the mean±SEM of at least three independent experiments. The results generated were analyzed using either the stu- Similarly, incubation of EA.hy926 monolayers with enoxaparin and dalteparin (at equivalent concentrations) also led to a significant attenuation of thrombin-induced endothelial permeability ( Figure 1D ). 
| LMWH-meditated suppression of thrombin-induced endothelial permeability is not mediated through a direct inhibition of thrombin proteolytic activity
| LMWH inhibits thrombin-induced endothelial cell MLC-2 diphosphorylation
Agonists such as thrombin, which induce endothelial cell contraction, activate signalling pathways which lead to the diphosphorylation and activation of myosin light chain-2 (MLC-2, the primary regulator of actin cytoskeleton contraction) and actin cytoskeleton activation.
As expected, minimal MLC-2 diphosphorylation was observed in untreated endothelial cells in the absence of stimulation with thrombin ( Figure 2A and B). Stimulation with thrombin (1 nmol/L; 10 minutes) led to a marked increase in endothelial MLC-2 diphosphorylation, but this was significantly attenuated in endothelial cells which had been pre-treated with tinzaparin (10 IU/ mL; 3-hour incubation) prior to incubation with thrombin (mean maximum thrombin-induced MLC-diphosphorylation reduced from 100±19.5% to 51.4±9.9%, P<.03; Figure 2A and B), suggesting that LMWH suppresses the activity of thrombin-activated signalling pathways which promote MLC-2 phosphorylation and actin cytoskeleton activation.
| Thrombin-mediated endothelial permeability is entirely PAR-1 dependent
In the presence of a cleavage-blocking anti-PAR1 antibody (ATAP2, thrombin receptor antibody; 20 μg/mL), thrombin-induced endothelial permeability was completely abolished. Similarly, a PAR-1 inhibitory peptide (RWJ56110; 20 μmol/L) also inhibited thrombininduced permeability, confirming that thrombin-mediated endothelial barrier permeability is entirely dependent on PAR-1 cleavage and the subsequent activation of PAR-1 intracellular signalling ( Figure 3A ). 
| LMWH-mediated attenuation of thrombininduced endothelial permeability is not achieved through inhibition of thrombin-mediated PAR-1 cleavage
Predictably, a significant reduction in mean fluorescence intensity (as determined by flow cytometry using an antibody detecting PAR-1 acti- Similarly, in the plasma anti-FXa activity assay, the 2.8 KDa fraction exhibited reduced anticoagulant activity ( Figure 5D ) relative to standard tinzaparin ( Figure 5C ). At a plasma concentration of 5 μg/mL, the fraction exhibited 0.18±0.01 IU/mL of anti-FXa activity, a value which would not be expected to confer a significant bleeding risk ( Figure 5D ).
However, despite diminished in vitro anticoagulant activity, the
KDa LMWH fraction did exhibit endothelial barrier protective
properties. At a concentration of 20 μg/mL, basal albumin permeability of the endothelial monolayer was unchanged ( Figure 5E ), however, thrombin-induced endothelial monolayer permeability was significantly attenuated, although to a lesser extent than that observed with the standard tinzaparin formulation (64±9%, P<.05; Figure 5F ) and, moreover, tumor cell trans-endothelial migration (63.9±3% of baseline, P<.001; Figure 5G ) was also significantly attenuated.
| Simvastatin attenuates endothelial permeability and exhibits synergistic inhibitory effects on agonist-induced endothelial permeability when co-incubated with sub-anticoagulant concentrations of LMWH
Following incubation of EA.hy926 monolayers with simvastatin, at a concentration range similar to the predicted plasma statin concentrations achieved in clinical practice, a modest concentration-dependent attenuation of thrombin-induced endothelial permeability was observed ( Figure 6A ).
F I G U R E 4 Low molecular weight heparin (LMWH)-mediated endothelial barrier protection is not mediated through an interaction with cell
surface heparan sulphate proteoglycans. Heparan sulphate proteoglycans cleavage attenuated thrombin-induced endothelial permeability (A). The relative attenuation of thrombin-induced endothelial permeability following incubation with LMWH was similar in heparinase III treated and untreated endothelial monolayers (B) (**P<.01; ***P<.001) was reduced to just 7.9±0.2% of baseline (P<.05; Figure 6A ). 
| DISCUSSION
In the present study, we have demonstrated in vitro evidence to suggest that the exposure of endothelium to LMWH leads to enhanced endothelial barrier function. Moreover, we have described the endothelial barrier protective properties of a tinzaparin-derived LMWH fraction with limited anticoagulant activity and we have characterized the additive endothelial protective effect which is observed following exposure of endothelium to combinations of LMWH and simvastatin.
Tumor cells which enter the circulation must attach to the vascular wall and extravasate through the impermeable barrier presented by normal endothelium in order for metastasis to proceed. 2, 34 The vital importance of the barriers to metastasis present at the stage of extravasation is reflected in the observation that only a tiny minority of circulating cancer cells (<0.01%) successfully establish secondary tumors. 2, 3, [34] [35] [36] Therefore, therapeutic strategies which directly enhance the activity of these physiological barriers to tumor cell extravasation would be predicted to attenuate cancer metastasis. inhibition of these various mechanisms in animal models of metastasis has been shown to attenuate tumor-mediated vascular permeability and metastasis formation.
6,9,37,38
The observation that LMWH attenuates endothelial permeability induced by multiple agonists and also attenuates tumor trans-endothelial migration suggests that LMWH may mediate a supportive effect on barrier function through a general mechanism involved in maintaining barrier integrity. Thrombin is one of the most potent physiological inducers of vascular permeability and the molecular mechanism underlying its activity in this regard is well characterized. 39, 40 Moreover, thrombin is the key effector protease of the blood coagulation cascade and the inhibition of thrombin generation and thrombin proteolytic activity forms the basis of anticoagulant therapy. 41, 42 Given that the risk of hemorrhage associated with anticoagulation represents the main disadvantage of LMWH use for the purposes of its anti-metastatic effect, we specifically investigated the mechanism underlying LMWH-mediated inhibition of thrombininduced endothelial permeability in order to ascertain if it might be possible to separate the anticoagulant and cytoprotective properties of LMWH in a manner which would facilitate the safe administration of this agent to patients with cancer at high risk of bleeding.
Interestingly, the barrier protective properties of LMWH in inhibiting thrombin-induced endothelial permeability did not appear to be mediated through the inhibition of its activation of PAR-1 nor did it appear to be mediated through an effect on HSPG cofactor activity in facilitating agonist-induced signalling. These findings, in conjunction with the observation that exposure of endothelial monolayers to LMWH also directly attenuates cellular trans-endothelial migration, suggest that LMWH mediates its cytoprotective effect on barrier function by independently signalling on the endothelial cell surface (a hypothesis which is supported by recent reports describing for the first time the expression of a specific heparin receptor on the endothelial cell surface which appears to modulate inflammatory responses including actin cytoskeleton rearrangement). 43 Crucially, LMWH appears to attenuate thrombin-induced endothelial permeability in a manner which is not dependent on inhibition of thrombin-proteolytic activity a finding which suggests that the cytoprotective and anticoagulant
properties of LMWH may not be inter-dependent.
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We have described the relative anticoagulant and cytoprotective of a fraction of LMWH derived from standard commercial tinzaparin but consisting primarily of shorter heparin polysaccharides than those which would be predicted to be observed in the commercial formula- function, such as components of the RhoA GTPase signalling pathway. Statin-mediated inhibition of these processes appears to diminish agonist-induced endothelial barrier dysfunction and endothelial inflammatory responses. 24, 25 We demonstrated that simvastatin attenuates thrombin-induced endothelial barrier dysfunction in vitro, although this observation only reached statistical significance at a simvastatin concentration at the upper limit of the therapeutic range. 45, 46 However, we also demonstrated that a synergistic effect on endothelial barrier function is observed when simvastatin and LMWH are co-incubated with endothelial cell monolayers and that almost complete protection against thrombin-induced endothelial barrier dysfunction can be achieved in vitro when combining a concentration of LMWH tinzaparin which would not be predicted to confer a risk of hemorrhage in vivo (0.1 IU/mL) and a concentration of simvastatin within the therapeutic range.
This study has some limitations: firstly, the putative receptor and signalling pathway for LMWH-mediated endothelial barrier protection remain to be fully characterized. Secondly, in vivo data supporting a synergistic role for LMWH and simvastatin in enhancing the endothelial barrier are currently lacking, although future work is planned. In addition, with regard to the clinical implications of our study, the interpretation of our findings is somewhat limited by the conflicting reports from clinical studies to date, some of which failed to detect a survival benefit following LMWH administration to cancer patients. 47, 48 However, in contrast to animal models of metastasis (which have con- Crucially, we have also described strategies which would be predicted to limit the risk of LMWH-associated haemorrhage without diminishing these LMWH-mediated cytoprotective activities; findings which, if replicated in vivo, would be of significant translational value.
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